Innovative Disease Models MIMETAS specializes in developing physiologically relevant 3D human disease models and organ-on-a-chip technology, providing a unique offering that appeals to pharmaceutical companies seeking advanced platforms for drug discovery and testing of untreatable diseases.

Strategic Collaborations The company's recent partnerships with Roche and Astellas Pharma demonstrate its capability to work with major industry players, signaling opportunities to introduce its platform and services to other pharmaceutical firms aiming to accelerate their research pipelines.

Product Expansion With the launch of ASC-derived organoids and tubules, MIMETAS is expanding its product portfolio, creating opportunities to sell ready-to-use, innovative organ-on-a-chip solutions to biotech and pharma companies focused on personalized medicine and high-throughput screening.

Industry Recognition Winning the Dutch Innovation Award 2022 enhances MIMETAS’ credibility and market visibility, making it an attractive partner for organizations interested in pioneering advanced drug development technologies.

Funding and Growth Potential With a recent funding of $2.3M and revenue in the 1M to 10M range, MIMETAS is positioned for growth and investment opportunities, especially as demand for organ-on-a-chip platforms rises in the pharmaceutical and biotech sectors seeking more predictive models.